DrugPatentWatch Database Preview
AMELUZ Drug Profile
When do Ameluz patents expire, and what generic alternatives are available?
Ameluz is a drug marketed by Biofrontera and is included in one NDA. There is one patent protecting this drug.
This drug has thirteen patent family members in eleven countries.
The generic ingredient in AMELUZ is aminolevulinic acid hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aminolevulinic acid hydrochloride profile page.
Summary for AMELUZ
| International Patents: | 13 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 73 |
| Clinical Trials: | 11 |
| Patent Applications: | 4,731 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for AMELUZ |
| DailyMed Link: | AMELUZ at DailyMed |
Recent Clinical Trials for AMELUZ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Jeffrey B. Travers, MD, PhD | Early Phase 1 |
| Royal Cornwall Hospitals Trust | Phase 3 |
| National Cancer Institute (NCI) | Phase 2 |
Pharmacology for AMELUZ
| Drug Class | Porphyrin Precursor |
Synonyms for AMELUZ
| 106-60-5 |
| 106A605 |
| 1354778-41-8 |
| 1451AA |
| 33871-EP2275420A1 |
| 33871-EP2295055A2 |
| 33871-EP2295416A2 |
| 33871-EP2298748A2 |
| 33871-EP2298764A1 |
| 33871-EP2298765A1 |
| 33871-EP2305642A2 |
| 33871-EP2305825A1 |
| 33871-EP2311453A1 |
| 33871-EP2311808A1 |
| 33871-EP2311829A1 |
| 35BEC718-C970-426A-9859-BF58284C60B4 |
| 4-Carboxy-2-Oxobutylamine |
| 4-oxo-5-amino-pentanoic acid |
| 5-ALA |
| 5-amino-4-oxo-Pentanoate |
| 5-amino-4-oxo-pentanoic acid |
| 5-Amino-4-oxopentanoate |
| 5-Amino-4-oxopentanoic acid |
| 5-Amino-4-oxopentanoic acid5-amino-4-oxo-pentanoic acid5-amino-4-keto-valeric acid106-60-5CHEBI:17549KBioSS_002062Spectrum_001582Pentanoic acid, 5- |
| 5-Amino-4-oxovalerate |
| 5-Amino-4-oxovaleric acid |
| 5-amino-levulinate |
| 5-amino-levulinic acid |
| 5-Aminolaevulinate |
| 5-Aminolaevulinic acid |
| 5-Aminolevulinate |
| 5-Aminolevulinic acid |
| 5-aminolevulinicacidhydrochloride |
| 5-azanyl-4-oxidanylidene-pentanoic acid |
| 5ALA |
| 88755TAZ87 |
| AB00053763_09 |
| AB00053763_10 |
| AB00053763-07 |
| AB00053763-08 |
| AC-054 |
| AC1L18K9 |
| AJ-45595 |
| AK-41254 |
| AKOS003587520 |
| Aladerm |
| ALBB-023627 |
| Amino-levulinic acid |
| Aminolevulinate |
| Aminolevulinic |
| Aminolevulinic acid |
| AN-16185 |
| AN-492 |
| AS-30950 |
| AX8017444 |
| BC205541 |
| BCP23830 |
| BDBM50240386 |
| BF-200 ALA |
| BIDD:GT0260 |
| BSPBio_003407 |
| C-49907 |
| C00430 |
| CCRIS 8958 |
| CHEBI:17549 |
| CHEMBL601 |
| CPD000857229 |
| CS-W000450 |
| D-aminolevulinic acid |
| D07567 |
| DALA |
| DB-040692 |
| DB00855 |
| delta-ALA |
| delta-aminolevulinate |
| delta-aminolevulinic acid |
| DivK1c_006954 |
| DTXSID8048490 |
| EINECS 203-414-1 |
| FCH831578 |
| FT-0620021 |
| FVT |
| GTPL4784 |
| HMS2231I19 |
| HMS3259E22 |
| HMS3369O14 |
| HY-W000450 |
| I14-10101 |
| KB-244624 |
| KBio1_001898 |
| KBio2_002062 |
| KBio2_004630 |
| KBio2_007198 |
| KBio3_002627 |
| KBioGR_001176 |
| KBioSS_002062 |
| Kerastick |
| Levulinic acid, 5-amino- |
| Levulinic acid, 5-amino- (8CI) |
| LMFA01100055 |
| LS-101793 |
| LS41389 |
| MCULE-8676354165 |
| MLS001333097 |
| MLS001333098 |
| MolPort-001-788-423 |
| NC00601 |
| NCGC00178086-01 |
| PEN029 |
| Pentanoic acid, 5-amino-4-oxo- |
| Pentanoic acid, 5-amino-4-oxo- (9CI) |
| SAM002589919 |
| SBB071696 |
| SBI-0206721.P001 |
| SC-15622 |
| SCHEMBL8243 |
| SMR000857229 |
| SPBio_001843 |
| SpecPlus_000858 |
| Spectrum_001582 |
| Spectrum2_001662 |
| Spectrum3_001654 |
| Spectrum4_000618 |
| Spectrum5_001505 |
| ST45026832 |
| UNII-88755TAZ87 |
| Z-3294 |
| ZGXJTSGNIOSYLO-UHFFFAOYSA-N |
| ZINC3782550 |
| ZX-AN022141 |
US Patents and Regulatory Information for AMELUZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biofrontera | AMELUZ | aminolevulinic acid hydrochloride | GEL;TOPICAL | 208081-001 | May 10, 2016 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| Biofrontera | AMELUZ | aminolevulinic acid hydrochloride | GEL;TOPICAL | 208081-001 | May 10, 2016 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for AMELUZ
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 1128812 | See Pricing |
| Japan | 2002529495 | See Pricing |
| South Africa | 200104726 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
